Article Information
- December 13, 2022.
Author Information
- Harry Bowlesa,**,
- Sarah Opie-Martina,**,
- Ali Shojaiea,
- Laura Libonatib,
- Alfredo Iacoangelia,c,d,
- Ahmad Al Khleifata and
- Ammar Al-Chalabia,e,*
- aDepartment of Basic and Clinical Neuroscience, King’s College London, London, UK
- bDepartment of Human Neurosciences, Sapienza University, Rome, Italy
- cDepartment of Biostatistics and Health Informatics, King’s College London, London, UK
- dNIHR Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London, London, UK
- eDepartment of Neurology, King’s College Hospital, London, UK
- ↵*corresponding author: ammar.al-chalabi{at}kcl.ac.uk
↵** both authors contributed equally to this work
Ammar Al-Chalabi is Professor of Neurology and Complex Disease Genetics at King’s College London, and Consultant Neurologist at King’s College Hospital, London, where he is Director of the King’s Motor Nerve Clinic. His clinical and research focus is amyotrophic lateral sclerosis (ALS). His team has developed a clinical staging system for ALS, and with others, a fundamental mechanistic hypothesis of ALS causation, showing it is likely a 6-step multistep process in which genetic factors may account for more than one step. He co-leads the international Project MinE consortium, sequencing more than 22,000 whole genomes, most from people with ALS, and with his team, has contributed to the identification of most known ALS genes.
